Stocks of ATAI Life Sciences N.V (NASDAQ:ATAI) traded higher last session on Wall Street, down -2.39% to $2.04.
ATAI stock price is now 24.19% away from the 50-day moving average and 39.55% away from the 200-day moving average. The market capitalization of the company currently stands at $395.75M.
With the price target reduced from $15 to $10, H.C. Wainwright maintained Buy rating for ATAI Life Sciences N.V (NASDAQ: ATAI). On April 03, 2024, Maxim Group Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock keeping its target price maintained at $6, while ‘Loop Capital’ rates the stock as ‘Buy’
In other news, Apeiron Investment Group Ltd., 10% Owner bought 10,835,718 shares of the company’s stock on Feb 14 ’25. The stock was bought for $22,755,008 at an average price of $2.10. Upon completion of the transaction, the 10% Owner now directly owns 40,555,215 shares in the company, valued at $82.73 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 26 ’24, 10% Owner ATAI Life Sciences N.V. sold 2,660,000 shares of the business’s stock. A total of $16,093,000 was realized by selling the stock at an average price of $6.05. This leaves the insider owning 6,905,774 shares of the company worth $14.09 million. A total of 30.65% of the company’s stock is owned by insiders.
During the past 12 months, ATAI Life Sciences N.V has had a low of $1.03 and a high of $2.85. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 5.81, and a quick ratio of 5.81.
The net profit margin was -38852.87% and return on equity was -62.43% for ATAI. The company reported revenue of $40000.0 for the quarter, compared to $87000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -54.02 percent.
